This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
June 2, 2011 /PRNewswire/ --
Marshall Edwards, Inc.(Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the appointment of
Robert Mass, M.D., as Chief Medical Officer. Dr. Mass joins
Marshall Edwards after more than a decade at Genentech, where he played a leading role in the clinical development of blockbuster oncology drugs Herceptin
® and Avastin
®. Dr. Mass has served as a consultant for
Marshall Edwards since
"Dr. Mass is the ideal choice to be
Marshall Edwards' Chief Medical Officer," said
Daniel P. Gold, Ph.D., President and Chief Executive Officer. "He brings in comparable expertise in all facets of oncology drug development, from creating an efficient clinical development strategy to managing multiple concurrent trials to effectively communicating with the FDA. In addition, Dr. Mass further bolsters our oncology presence with invaluable, hands-on experience treating patients. His appointment, combined with the recent closing of our private placement and asset purchase transactions, positions us very well as we prepare for the next phase of development."
Dr. Mass has more than 20 years of experience as a medical oncologist in both clinical practice and clinical drug development. He held a number of leadership positions at Genentech from 1998 to 2009, most recently as Head of Medical Affairs, BioOncology, a position created to strategically integrate and optimize all of the non-sponsored clinical programs within the company's oncology portfolio. He also served on the Executive Development Review Committee at Genentech, which was responsible for the review and approval of all sponsored clinical programs across the company's therapeutic portfolio. Previously he served as clinical science leader for Herceptin from 1999 to 2002, Tarceva from 2002 to 2003, and Avastin, currently the leading oncology therapeutic worldwide, from 2003 to 2007. Prior to joining Genentech, he practiced Hematology and Medical Oncology from 1988 to 1998. Dr. Mass earned his bachelor's degree in economics from
Tufts University and his medical degree from Oregon Health & Science University. He is certified by the American Board of Internal Medicine in both Internal Medicine and Medical Oncology.
The Company also announced the approval of non-qualified stock option grants to Dr. Mass in accordance with Nasdaq Listing Rule 5635(c)(4).